Seastar Medical Hldg Corp (ICU)

$0.24 +0.01 (2.89%)
Market Cap 8.48M
Revenue (ttm) 140,000.00
Net Income (ttm) -24.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -17,735.71%
Debt to Equity Ratio 0.00
Volume 1,276,600
Avg Vol 1,994,212
Day's Range N/A - N/A
Shares Out 36.05M
Stochastic %K 17%
Beta -1.03
Analysts Strong Sell
Price Target $1.00

Company Profile

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI)...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 427 8100
Address:
3513 Brighton Boulevard, Suite 410, Denver, United States
Bazzzigar
Bazzzigar Dec. 25 at 4:16 AM
$ICU below $0.18 before Jan 5th...
1 · Reply
josh77
josh77 Dec. 25 at 1:58 AM
$ICU 5‑Year Revenue Projection (Using 48.4% CAGR) Year Projected Revenue Notes 2025 (base) $0.88M Current trailing 12‑month revenue 2026 $1.31M Early commercialization, small contracts 2027 $1.94M Growth from initial adoption 2028 $2.88M Scaling clinical use, more hospitals 2029 $4.28M Reimbursement + broader AKI penetration 2030 $6.35M Expansion into adult AKI or new indications
2 · Reply
josh77
josh77 Dec. 25 at 1:10 AM
$ICU Bullish Long‑Term Scenario If ICU successfully: Completes the pivotal trial Secures FDA approval Launches commercially Gains reimbursement Expands into adult AKI and other inflammatory conditions Then the earnings potential becomes transformational, not incremental. Under this scenario, ICU could shift from: Negative EPS today to High‑margin recurring revenue Strong EPS growth Potential profitability This aligns with the forecasted 44% annual EPS growth
0 · Reply
josh77
josh77 Dec. 25 at 1:08 AM
$ICU Why the Long‑Term Potential Is Big ICU’s SCD platform targets Acute Kidney Injury, a market worth billions annually. The NEUTRALIZE‑AKI pivotal trial is the key value driver, and although enrollment expanded (delaying completion to 2026), the upside remains enormous if the device proves effective. If SCD becomes a standard‑of‑care device for AKI: Hospitals could adopt it widely Reimbursement could be strong ICU could generate recurring revenue per treatment Margins on medical devices are typically high This is where the true earnings potential lies.
0 · Reply
josh77
josh77 Dec. 25 at 1:06 AM
$ICU Bullish Bottom Line A 10‑for‑1 reverse split could position ICU for: Higher visibility Stronger compliance A dramatically reduced float More institutional access Bigger post‑split volatility A cleaner setup for catalysts If ICU has news, trial updates, or partnerships in the pipeline, a reverse split can actually amplify the impact.
0 · Reply
techjerk
techjerk Dec. 24 at 10:03 PM
$ICU Brad .. with no short or position .. a little Christmas cheer. U excite me .. https://www.youtube.com/watch?v=JWoYy4Ah81s
0 · Reply
techjerk
techjerk Dec. 24 at 9:52 PM
$ICU huh
0 · Reply
techjerk
techjerk Dec. 24 at 9:51 PM
$ICU
0 · Reply
MountainLions
MountainLions Dec. 24 at 8:28 PM
$ICU Anybody know when the R/S is happening ?
1 · Reply
techjerk
techjerk Dec. 24 at 8:00 PM
$ICU A fitting song title Seastar? https://www.youtube.com/watch?v=UDUrVnsNZcI&list=RDUDUrVnsNZcI&start_radio=1
1 · Reply
Latest News on ICU
SeaStar Medical Announces 1-for-10 Reverse Split

Dec 23, 2025, 4:25 PM EST - 1 day ago

SeaStar Medical Announces 1-for-10 Reverse Split

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

Dec 2, 2025, 8:27 AM EST - 22 days ago

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

Nov 20, 2025, 9:52 AM EST - 4 weeks ago

SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

SeaStar Medical Announces Appointment of Michael Messinger as CFO

Nov 17, 2025, 8:43 AM EST - 5 weeks ago

SeaStar Medical Announces Appointment of Michael Messinger as CFO

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 13, 2025, 4:05 PM EST - 5 weeks ago

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

Nov 5, 2025, 10:03 AM EST - 7 weeks ago

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

Sep 29, 2025, 8:36 AM EDT - 3 months ago

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

Sep 24, 2025, 4:22 PM EDT - 3 months ago

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

Sep 23, 2025, 8:23 AM EDT - 3 months ago

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 6:13 PM EDT - 3 months ago

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

Sep 2, 2025, 8:22 AM EDT - 4 months ago

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 4:05 PM EDT - 4 months ago

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

Aug 7, 2025, 10:00 AM EDT - 4 months ago

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

Aug 6, 2025, 8:33 AM EDT - 5 months ago

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 31, 2025, 3:01 PM EDT - 5 months ago

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

Jul 22, 2025, 8:20 AM EDT - 5 months ago

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

Jul 16, 2025, 8:45 AM EDT - 5 months ago

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 10, 2025, 3:29 PM EDT - 5 months ago

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

Jul 8, 2025, 8:05 AM EDT - 6 months ago

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces Positive Nasdaq Listing Determination

Jul 2, 2025, 4:25 PM EDT - 6 months ago

SeaStar Medical Announces Positive Nasdaq Listing Determination

SeaStar Medical Reports Update on Nasdaq Listing Status

Jun 25, 2025, 8:05 AM EDT - 6 months ago

SeaStar Medical Reports Update on Nasdaq Listing Status

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

Jun 24, 2025, 9:05 AM EDT - 6 months ago

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

Jun 20, 2025, 12:10 PM EDT - 6 months ago

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research

Jun 11, 2025, 8:25 AM EDT - 7 months ago

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

May 28, 2025, 8:05 AM EDT - 7 months ago

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:49 PM EDT - 8 months ago

SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025, 4:05 PM EDT - 8 months ago

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

May 13, 2025, 8:05 AM EDT - 8 months ago

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

May 7, 2025, 10:00 AM EDT - 8 months ago

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

Apr 30, 2025, 8:05 AM EDT - 8 months ago

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

Apr 8, 2025, 8:05 AM EDT - 9 months ago

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 27, 2025, 4:05 PM EDT - 9 months ago

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 24, 2025, 5:30 PM EDT - 9 months ago

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

Mar 18, 2025, 8:45 AM EDT - 10 months ago

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

Feb 3, 2025, 4:05 PM EST - 11 months ago

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

Jan 22, 2025, 7:30 AM EST - 1 year ago

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

Jan 13, 2025, 8:30 AM EST - 1 year ago

FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

Jan 8, 2025, 8:30 AM EST - 1 year ago

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

Dec 23, 2024, 7:00 AM EST - 1 year ago

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

Dec 11, 2024, 6:30 AM EST - 1 year ago

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

Dec 4, 2024, 8:30 AM EST - 1 year ago

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024

Nov 26, 2024, 8:00 AM EST - 1 year ago

SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

Nov 22, 2024, 8:30 AM EST - 1 year ago

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

Nov 15, 2024, 8:30 AM EST - 1 year ago

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 13, 2024, 5:05 PM EST - 1 year ago

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

Oct 31, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

Oct 25, 2024, 11:32 AM EDT - 1 year ago

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

Oct 22, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

Bazzzigar
Bazzzigar Dec. 25 at 4:16 AM
$ICU below $0.18 before Jan 5th...
1 · Reply
josh77
josh77 Dec. 25 at 1:58 AM
$ICU 5‑Year Revenue Projection (Using 48.4% CAGR) Year Projected Revenue Notes 2025 (base) $0.88M Current trailing 12‑month revenue 2026 $1.31M Early commercialization, small contracts 2027 $1.94M Growth from initial adoption 2028 $2.88M Scaling clinical use, more hospitals 2029 $4.28M Reimbursement + broader AKI penetration 2030 $6.35M Expansion into adult AKI or new indications
2 · Reply
josh77
josh77 Dec. 25 at 1:10 AM
$ICU Bullish Long‑Term Scenario If ICU successfully: Completes the pivotal trial Secures FDA approval Launches commercially Gains reimbursement Expands into adult AKI and other inflammatory conditions Then the earnings potential becomes transformational, not incremental. Under this scenario, ICU could shift from: Negative EPS today to High‑margin recurring revenue Strong EPS growth Potential profitability This aligns with the forecasted 44% annual EPS growth
0 · Reply
josh77
josh77 Dec. 25 at 1:08 AM
$ICU Why the Long‑Term Potential Is Big ICU’s SCD platform targets Acute Kidney Injury, a market worth billions annually. The NEUTRALIZE‑AKI pivotal trial is the key value driver, and although enrollment expanded (delaying completion to 2026), the upside remains enormous if the device proves effective. If SCD becomes a standard‑of‑care device for AKI: Hospitals could adopt it widely Reimbursement could be strong ICU could generate recurring revenue per treatment Margins on medical devices are typically high This is where the true earnings potential lies.
0 · Reply
josh77
josh77 Dec. 25 at 1:06 AM
$ICU Bullish Bottom Line A 10‑for‑1 reverse split could position ICU for: Higher visibility Stronger compliance A dramatically reduced float More institutional access Bigger post‑split volatility A cleaner setup for catalysts If ICU has news, trial updates, or partnerships in the pipeline, a reverse split can actually amplify the impact.
0 · Reply
techjerk
techjerk Dec. 24 at 10:03 PM
$ICU Brad .. with no short or position .. a little Christmas cheer. U excite me .. https://www.youtube.com/watch?v=JWoYy4Ah81s
0 · Reply
techjerk
techjerk Dec. 24 at 9:52 PM
$ICU huh
0 · Reply
techjerk
techjerk Dec. 24 at 9:51 PM
$ICU
0 · Reply
MountainLions
MountainLions Dec. 24 at 8:28 PM
$ICU Anybody know when the R/S is happening ?
1 · Reply
techjerk
techjerk Dec. 24 at 8:00 PM
$ICU A fitting song title Seastar? https://www.youtube.com/watch?v=UDUrVnsNZcI&list=RDUDUrVnsNZcI&start_radio=1
1 · Reply
littleguyfinance
littleguyfinance Dec. 24 at 7:46 PM
$ICU I added yesterday AH at $0.19. Will Keep buying dips. Target price $50M Mcap, which is more than 5x from here. I still think the tech is worth $100M - $300M and we will see that value if trial enrollment speeds up dramatically and/or PED revenues ramp up. Merry Christmas!
0 · Reply
SparkyReturns
SparkyReturns Dec. 24 at 6:01 PM
$ICU Merry Christmas! Rocket fuel on the way in 2026! https://www.youtube.com/watch?v=yDRJItKqClk
1 · Reply
ubifi
ubifi Dec. 24 at 5:49 PM
$ICU ok. This will stay above 1usd for 10 days after RS. Maybe some atack in the first couple of days. After that Im expecting wild ride upward. Hang on.
0 · Reply
richard52
richard52 Dec. 24 at 5:45 PM
$ICU Looks like we will close as green as a Christmas tree or as a Winner’s Garland which we will earn in coming weeks and months. Best wishes to all! Merry Berries!
0 · Reply
Unitypal
Unitypal Dec. 24 at 5:04 PM
$ICU 1 hour.
0 · Reply
badprecog
badprecog Dec. 24 at 3:36 PM
$ICU Does anyone know if the 339 was part of a tiers system, or if they just went to that because the 25 percent improvement wasn’t happening or some other formula?
1 · Reply
Stocktud
Stocktud Dec. 24 at 3:17 PM
$ALT $IBRX $ICU $OMER I’m sorry. Not interested in UPC. I am so addicted to IBRX. WAITING FOR UP FRONT MONEY FROM EUROPE PARTNERSHIP IN NEW YEAR! Please exclude Ibrx from your future post. Much appreciated! See attached! Thanks bro!
1 · Reply
ParabolicalSpartan
ParabolicalSpartan Dec. 24 at 3:07 PM
What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems $OMER $ALT $IBRX $ICU too
1 · Reply
BigJohn57
BigJohn57 Dec. 24 at 1:49 PM
$ICU No Merry Christmas here!
0 · Reply
Unitypal
Unitypal Dec. 24 at 1:19 PM
$ICU Merry Christmas 🎄 to all 🎁
1 · Reply
YandH
YandH Dec. 24 at 1:09 PM
$ICU Make your voice be heard. https://p4qm.org/prmr-measures/muc2025-047
0 · Reply
Jstockdaddy
Jstockdaddy Dec. 24 at 12:48 PM
$ICU the manipulation in this stock should be studied. I get it’s a micro cap so it’s easy to move around but that drop last night was CRIMINAL. I think big news is around the corner hence the expedited split lower the float make it explode hoping for one of those crazy pumps but I’ll take what we get. Chung has been silent something feels like it’s brewing. The don’t need immediate cash so why would they dilute right away ? Not sayin dilution isn’t coming at some point but hoping they can get some other forms of funding considering the success of the device.
2 · Reply